INTEGRA LIFESCIENCES HOLDING (IART) Stock Fundamental Analysis
NASDAQ:IART • US4579852082
12.05 USD
+0.06 (+0.5%)
At close: Feb 19, 2026
12.05 USD
0 (0%)
After Hours: 2/19/2026, 8:06:47 PM
IART gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 185 industry peers in the Health Care Equipment & Supplies industry. While IART is still in line with the averages on profitability rating, there are concerns on its financial health. IART has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
- IART had positive earnings in the past year.
- In the past year IART had a positive cash flow from operations.
- IART had positive earnings in 4 of the past 5 years.
- Each year in the past 5 years IART had a positive operating cash flow.
1.2 Ratios
- With a Return On Assets value of -13.58%, IART perfoms like the industry average, outperforming 58.38% of the companies in the same industry.
- IART has a Return On Equity (-47.74%) which is in line with its industry peers.
- With a decent Return On Invested Capital value of 4.27%, IART is doing good in the industry, outperforming 74.05% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for IART is below the industry average of 8.75%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROIC | 4.27% |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
1.3 Margins
- IART has a better Operating Margin (10.22%) than 78.92% of its industry peers.
- In the last couple of years the Operating Margin of IART has declined.
- The Gross Margin of IART (57.21%) is comparable to the rest of the industry.
- In the last couple of years the Gross Margin of IART has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% |
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so IART is destroying value.
- IART has less shares outstanding than it did 1 year ago.
- IART has less shares outstanding than it did 5 years ago.
- IART has a worse debt/assets ratio than last year.
2.2 Solvency
- Based on the Altman-Z score of 1.24, we must say that IART is in the distress zone and has some risk of bankruptcy.
- IART's Altman-Z score of 1.24 is in line compared to the rest of the industry. IART outperforms 55.14% of its industry peers.
- A Debt/Equity ratio of 1.73 is on the high side and indicates that IART has dependencies on debt financing.
- With a Debt to Equity ratio value of 1.73, IART is not doing good in the industry: 80.54% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.24 |
ROIC/WACC0.55
WACC7.76%
2.3 Liquidity
- A Current Ratio of 3.14 indicates that IART has no problem at all paying its short term obligations.
- IART has a Current ratio (3.14) which is comparable to the rest of the industry.
- A Quick Ratio of 1.80 indicates that IART should not have too much problems paying its short term obligations.
- IART has a Quick ratio (1.80) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 |
3. Growth
3.1 Past
- IART shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -4.44%.
- IART shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -1.35% yearly.
- Looking at the last year, IART shows a small growth in Revenue. The Revenue has grown by 4.99% in the last year.
- IART shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 1.20% yearly.
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
3.2 Future
- Based on estimates for the next years, IART will show a small growth in Earnings Per Share. The EPS will grow by 2.68% on average per year.
- Based on estimates for the next years, IART will show a small growth in Revenue. The Revenue will grow by 2.39% on average per year.
EPS Next Y-12.33%
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
EPS Next 5Y2.68%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 5.08 indicates a rather cheap valuation of IART.
- IART's Price/Earnings ratio is rather cheap when compared to the industry. IART is cheaper than 98.92% of the companies in the same industry.
- IART's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.09.
- IART is valuated cheaply with a Price/Forward Earnings ratio of 5.03.
- Based on the Price/Forward Earnings ratio, IART is valued cheaply inside the industry as 99.46% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of IART to the average of the S&P500 Index (27.98), we can say IART is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.08 | ||
| Fwd PE | 5.03 |
4.2 Price Multiples
- 95.68% of the companies in the same industry are more expensive than IART, based on the Enterprise Value to EBITDA ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 7.72 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
5. Dividend
5.1 Amount
- IART does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
12.05
+0.06 (+0.5%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners95.82%
Inst Owner Change-0.03%
Ins Owners3.07%
Ins Owner Change0.13%
Market Cap938.57M
Revenue(TTM)1.64B
Net Income(TTM)-495.33M
Analysts54.12
Price Target15.81 (31.2%)
Short Float %11.41%
Short Ratio10.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.96%
Min EPS beat(2)2.22%
Max EPS beat(2)21.7%
EPS beat(4)3
Avg EPS beat(4)7.07%
Min EPS beat(4)-6.76%
Max EPS beat(4)21.7%
EPS beat(8)4
Avg EPS beat(8)3.13%
EPS beat(12)6
Avg EPS beat(12)3.64%
EPS beat(16)8
Avg EPS beat(16)4.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.86%
Min Revenue beat(2)-4.85%
Max Revenue beat(2)3.14%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-4.85%
Max Revenue beat(4)3.14%
Revenue beat(8)1
Avg Revenue beat(8)-1.23%
Revenue beat(12)2
Avg Revenue beat(12)-1.2%
Revenue beat(16)3
Avg Revenue beat(16)-0.96%
PT rev (1m)0%
PT rev (3m)-8.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1.23%
EPS NY rev (1m)0%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.08%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.24%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.08 | ||
| Fwd PE | 5.03 | ||
| P/S | 0.57 | ||
| P/FCF | N/A | ||
| P/OCF | 10.51 | ||
| P/B | 0.9 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.72 |
EPS(TTM)2.37
EY19.67%
EPS(NY)2.4
Fwd EY19.9%
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)1.15
OCFY9.52%
SpS21.09
BVpS13.32
TBVpS-9.47
PEG (NY)N/A
PEG (5Y)N/A
Graham Number26.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.58% | ||
| ROE | -47.74% | ||
| ROCE | 5.11% | ||
| ROIC | 4.27% | ||
| ROICexc | 4.65% | ||
| ROICexgc | 11.32% | ||
| OM | 10.22% | ||
| PM (TTM) | N/A | ||
| GM | 57.21% | ||
| FCFM | N/A |
ROA(3y)2.09%
ROA(5y)2.89%
ROE(3y)4.61%
ROE(5y)6.54%
ROIC(3y)6.1%
ROIC(5y)6.15%
ROICexc(3y)6.8%
ROICexc(5y)7%
ROICexgc(3y)25.35%
ROICexgc(5y)25.69%
ROCE(3y)7.3%
ROCE(5y)7.36%
ROICexgc growth 3Y-1.99%
ROICexgc growth 5Y0.59%
ROICexc growth 3Y-12.19%
ROICexc growth 5Y-7.26%
OM growth 3Y-14.31%
OM growth 5Y-7.91%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.19%
GM growth 5Y-1.66%
F-Score5
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.73 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 5.62 | ||
| Cap/Depr | 68.73% | ||
| Cap/Sales | 6.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 28.01% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 1.8 | ||
| Altman-Z | 1.24 |
F-Score5
WACC7.76%
ROIC/WACC0.55
Cap/Depr(3y)58.38%
Cap/Depr(5y)54.07%
Cap/Sales(3y)4.82%
Cap/Sales(5y)4.45%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.44%
EPS 3Y-6.97%
EPS 5Y-1.35%
EPS Q2Q%31.71%
EPS Next Y-12.33%
EPS Next 2Y-3.22%
EPS Next 3Y1.53%
EPS Next 5Y2.68%
Revenue 1Y (TTM)4.99%
Revenue growth 3Y1.45%
Revenue growth 5Y1.2%
Sales Q2Q%5.57%
Revenue Next Year1.09%
Revenue Next 2Y1.9%
Revenue Next 3Y2.45%
Revenue Next 5Y2.39%
EBIT growth 1Y-9.4%
EBIT growth 3Y-13.07%
EBIT growth 5Y-6.81%
EBIT Next Year17.61%
EBIT Next 3Y9.61%
EBIT Next 5Y8.11%
FCF growth 1Y-113.18%
FCF growth 3Y-61.56%
FCF growth 5Y-31.13%
OCF growth 1Y-46.39%
OCF growth 3Y-25.46%
OCF growth 5Y-10.98%
INTEGRA LIFESCIENCES HOLDING / IART FAQ
Can you provide the ChartMill fundamental rating for INTEGRA LIFESCIENCES HOLDING?
ChartMill assigns a fundamental rating of 4 / 10 to IART.
What is the valuation status for IART stock?
ChartMill assigns a valuation rating of 6 / 10 to INTEGRA LIFESCIENCES HOLDING (IART). This can be considered as Fairly Valued.
What is the profitability of IART stock?
INTEGRA LIFESCIENCES HOLDING (IART) has a profitability rating of 4 / 10.
What is the financial health of INTEGRA LIFESCIENCES HOLDING (IART) stock?
The financial health rating of INTEGRA LIFESCIENCES HOLDING (IART) is 3 / 10.